Daraxonrasib nearly doubles survival in metastatic pancreatic cancer trial
A Chicago audience rose to its feet as daraxonrasib nearly doubled survival in metastatic pancreatic cancer, a rare jump in a disease defined by small gains.
A standing ovation in Chicago greeted a result that few pancreatic cancer doctors have seen in years: daraxonrasib nearly doubled median overall survival in previously treated metastatic pancreatic ductal adenocarcinoma, lifting the median to 13.2 months from 6.7 months with standard chemotherapy. In a disease where second-line treatment usually buys only about 3 to 4 months of progression-free survival and 6 to 7 months of overall survival, that kind of gain is unusually meaningful.
The phase 3 RASolute 302 trial enrolled 500 patients in a global, randomized, open-label study and tested daraxonrasib, also known as RMC-6236, a once-daily oral RAS(ON) multi-selective inhibitor. Revolution Medicines said the trial met its primary endpoint and key secondary endpoints, including progression-free survival and overall survival. The company reported a hazard ratio of 0.40 for overall survival, with p less than 0.0001. The data were presented at the American Society of Clinical Oncology Annual Meeting, held May 29 to June 2, 2026, and published simultaneously in The New England Journal of Medicine.
That matters because pancreatic cancer remains one of oncology’s most unforgiving solid tumors. The American Cancer Society estimates about 67,530 people in the United States will be diagnosed with pancreatic cancer in 2026 and about 52,740 will die from it. More than 90% of pancreatic tumors carry KRAS mutations, and KRAS was long treated as undruggable. Earlier RAS inhibitors changed that story in other cancers, but most of those drugs focused on a KRAS mutation that is rare in pancreatic cancer. Daraxonrasib is different in that it shuts down KRAS signaling whether the tumor carries a KRAS variant or not.
The excitement was not just statistical. Reports from the meeting described a standing ovation, with some audience members in tears, and Harvard Medical School said the presentation drew that reaction in Chicago. Brian M. Wolpin of Dana-Farber Cancer Institute and Harvard Medical School called the results a highly meaningful step forward that may become practice-changing for physicians and improve care for patients with previously treated metastatic pancreatic cancer. Dana-Farber added that, if future trials support it, daraxonrasib could become a targeted therapy relevant to nearly all patients with advanced pancreatic cancer.
The phase 3 readout builds on earlier phase 1/2 data in 168 patients with previously treated RAS-mutated pancreatic cancer, where treatment-related grade 3 or higher adverse events occurred in 30% of patients. Among 26 second-line patients with RAS G12 mutations treated at 300 mg daily, the objective response rate was 35%, with median progression-free survival of 8.5 months and median overall survival of 13.1 months. Revolution Medicines plans to use the new findings in a future New Drug Application to the U.S. Food and Drug Administration and other regulators, setting up one of the clearest tests yet of whether precision medicine can finally take hold in pancreatic cancer.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
